ZyVersa Therapeutics
ZVSA
ZVSA was delisted on the 16th of July, 2025.
6 hedge funds and large institutions have $181K invested in ZyVersa Therapeutics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, reducing their positions, and 8 closing their positions.
12% more capital invested
Capital invested by funds: $162K → $181K (+$19.7K)
1.22% more ownership
Funds ownership: 0.01% → 1.23% (+1.2%)
33% less funds holding
Funds holding: 9 → 6 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$452K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$52.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$42.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$128K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$16.1K |
| 3 |
CAC
Cowen and Company
New York
|
-$6.47K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.23K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$2.19K |
ZVSA Hedge Fund Activity: Q4 2023 in Review
6 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q4 2023, worth a combined $181K — up 12% from $162K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ZVSA and 5 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $452K. The largest seller was Walleye Capital, exiting entirely with an estimated $128K sold.
- 6 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q4 2023, down from 9 in Q3 2023.
- Funds reported $181K of ZyVersa Therapeutics stock for Q4 2023, up 12% quarter-over-quarter.
- 5 funds opened new ZyVersa Therapeutics positions in Q4 2023 and 8 closed out, a net change of -3 holders.
- The largest ZyVersa Therapeutics buyer in Q4 2023 was Anson Funds Management, an estimated $452K added.
- The largest ZyVersa Therapeutics seller in Q4 2023 was Walleye Capital, an estimated $128K sold.
Based on aggregated 13F filings for Q4 2023.